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Methods: A total of 17,374 patients, comprising 10,578 treated
Asian patients with chronic hepatitis B (CHB), 2,510 treated
Caucasian patients with CHB, 3,566 treated patients with hepa-
titis C virus (including 2,489 patients with cirrhosis achieving a
sustained virological response) and 720 patients with non-viral
hepatitis (NVH) from 11 international prospective observational
cohorts or randomised controlled trials, were divided into a
training cohort (3,688 Asian patients with CHB) and 9 validation
cohorts with different aetiologies and ethnicities (n = 13,686).
Results: We developed an HCC risk score, called the aMAP score
(ranging from 0 to 100), that involves only age, male, albumin–
bilirubin and platelets. This metric performed excellently in
assessing HCC risk not only in patients with hepatitis of different
aetiologies, but also in those with different ethnicities (C-index:
0.82–0.87). Cut-off values of 50 and 60 were best for discrimi-
nating HCC risk. The 3- or 5-year cumulative incidences of HCC
were 0–0.8%, 1.5–4.8%, and 8.1–19.9% in the low- (n = 7,413,2020 vol. - j 1–11
Research Article Viral hepatitis43.6%), medium- (n = 6,529, 38.4%), and high-risk (n = 3,044,
17.9%) groups, respectively. The cut-off value of 50 was associ-
ated with a sensitivity of 85.7–100% and a negative predictive
value of 99.3–100%. The cut-off value of 60 resulted in a speci-
ficity of 56.6–95.8% and a positive predictive value of 6.6–15.7%.
Conclusions: This objective, simple, reliable risk score based on 5
common parameters accurately predicted HCC development,
regardless of aetiology and ethnicity,which could help to establish
a risk score-guided HCC surveillance strategy worldwide.
Lay summary: In this international collaboration, we developed
and externally validated a simple, objective and accurate prog-
nostic tool (called the aMAP score), that involves only age, male,
albumin–bilirubin and platelets. The aMAP score (ranged from
0 to 100) satisfactorily predicted the risk of hepatocellular car-
cinoma (HCC) development among over 17,000 patients with
viral and non-viral hepatitis from 11 global prospective studies.
Our findings show that the aMAP score had excellent discrimi-
nation and calibration in assessing the 5-year HCC risk among all
the cohorts irrespective of aetiology and ethnicity.
© 2020 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
With the vision of ‘ending viral hepatitis’, the World Health Or-
ganization (WHO) set the ambitious goal of reducing hepatitis-
related mortality by 65% by the year 2030.1 In the era of the
widespread application of antiviral treatment, hepatocellular
carcinoma (HCC) is the leading cause of death in patients with
chronic viral hepatitis and the fourth most frequent cause of
cancer-related death globally.2 Therefore, the key to achieving
the ambitious global goal proposed by the WHO is to reduce the
mortality of viral hepatitis-associated HCC.
The success of treatment for HCC largely depends on the stage
at which it is diagnosed. Patients with HCC diagnosed at an early
stage have 5-year survival rates of 70–75%,3,4 whereas the
average survival time of patients with advanced HCC is less than
1 year.5 An effective and successful HCC surveillance programme
could offer early diagnosis and improve prognosis. The key is an
easy and accurate tool to identify patients with different HCC
risks and then individualise HCC surveillance.
HBV and HCV infections are the leading causes of HCC
development. Over the past few decades, several HCC risk scores
have been developed and validated to stratify the risk of HCC
development.6–13 However, most of these risk scores assign
heavy weighting to viral factors and perform only satisfactorily
among populations with specific aetiologies (HBV or HCV) and
ethnicities (Asian or Caucasian), thus limiting their widespread
promotion and application worldwide in the current era of
sustained viral suppression or clearance by using antiviral
treatment.
In this international, multi-aetiological, multi-ethnic, pro-
spective chronic hepatitis cohort study, we aimed to develop and
validate a novel, accurate, globally applicable risk score for pre-
dicting HCC development.
Patients and methods
This study was based on 11 prospective observational cohorts or
randomised controlled trials (RCTs) involving patients with
chronic HBV (CHB; n = 7), chronic HCV (n = 3) and non-viral
hepatitis (NVH; n = 1).2 Journal of HepatologyCHB patients
Search-B cohort: a prospective multicentre observational cohort in
China
In this cohort study (NCT02167503), adult patients with CHB
were recruited fromMay 2014 to January 2018 from 15 centres in
8 provinces in China. All the patients enrolled in this cohort
received antiviral treatment at the discretion of their physicians
(71.3% treated with either entecavir or tenofovir) and underwent
follow-up for up to 5 years. The data included in the analysis
were as of July 2019.
REALM trial: a global randomized controlled trial (RCT)
In this trial (NCT00388674), adult patients with CHB enrolled
from 299 centres in 24 countries were screened and recruited
from December 2006 to July 2008. All eligible patients were
randomly assigned (1:1) to receive either entecavir or an
investigator-selected non-entecavir HBV nucleos(t)ide analogue
and followed for up to 10 years.14 The analysis included the data
from patients treated with entecavir from 50 centres in 16
provinces in China.
European PAGE-B cohort
This cohort study included adult patients with CHB followed in
10 European centres who had started treatment with either
entecavir or tenofovir between January 2004 and December
2012 and had completed at least 12 months of therapy, as pre-
viously described.15 The data included in the analysis were as of
May 2019.
Four global Gilead CHB RCTs
Adult patients with CHB from the 4 global RCTs sponsored by
Gilead Pharmacy (NCT00117676, NCT00116805, NCT01940341
and NCT01940471) were recruited from May 2005 to June 2006
(the first 2 trials) and from September 2013 to October 2014 (the
last 2 trials). The patients in the first 2 trials were randomised to
receive either double-blind tenofovir or adefovir for 1 year
before starting tenofovir open-label treatment for up to 9 years.
The patients in the last 2 trials were randomised to receive either
double-blind tenofovir or tenofovir alafenamide (TAF) for up to 3
years before starting TAF open-label treatment until year 8.16,17
The analysis was performed based on the anonymised data
including Asian and Caucasian patients who met the anonym-
isation criteria to protect patient privacy.
In the above 7 CHB cohorts/trials, patients with decom-
pensated cirrhosis, HCC, liver transplantation, or co-infection(s)
with hepatitis D, HCV or HIV were excluded. The laboratory re-
sults collected at enrolment were used for the analysis.
Patients with HCV
Japanese HCV cohort
Adult patients with HCV were enrolled from 1 centre in Japan
between 1998 and 2016. Adult patients who received either
interferon (IFN) or direct-acting antiviral agent (DAA) treatment
were enrolled in the analysis. The laboratory results collected after
the completion of antiviral treatment were used for the analysis.
UK HCV sustained virological response cirrhotic cohort
This cohort was assembled by combining patients with HCV, a
sustained virological response (SVR) and cirrhosis (88.5%
Caucasians) from 2 UK studies: (i) a previously described cohort
of patients with HCV cirrhosis from Scotland, achieving an SVR2020 vol. - j 1–11
Table 1. Clinical characteristics of patients in the training cohort and 9 validation cohorts.
Search-B
training cohort
Asian CHB validation cohort
Caucasian CHB validation
cohort HCV infection cohort
Japanese
NVH cohort
Search-B
validation cohort REALM cohort
Gilead Asian
CHB cohort
European
PAGE-B cohort
Gilead
Caucasian
CHB cohort
Japanese HCV
cohort
UK SVR
cirrhotic cohort
Gilead SVR
cirrhotic cohort
Total No. of patients 3,688 2,847 2,548 1,495 1,938 572 1,077 1,230 1,259 720
Male, n (%) 2,977 (80.7) 2,071 (72.7) 2,061 (80.9) 977 (65.4) 1,369 (70.6) 443 (77.4) 532 (49.4) 900 (73.2) 866 (68.8) 337 (46.8)
Age, years
Median 38 44 36 40 54 38 62 52 60 65
IQR 32, 46 37, 53 29, 43 32, 48 44, 63 28, 48 55, 70 46, 59 56, 63 57, 72
Cirrhosis, n (%) 710 (19.3) 565 (19.8) 307 (12.0) 167/1,466 (11.4) 518/1,892 (27.4) 98/558 (17.6) 195 (18.1) 1,230 (100) 1,259 (100) 189 (26.3)
Platelet, ×103/mm3
Median 186 162 170 191 187 201 180 136 137 216
IQR 144, 225 116, 203 127, 211 157, 228 153, 226 171, 239 140, 226 93, 185 94, 188 154, 267
Total No. with data 3670 2791 2469 1493 1865 571 1077 1230 1259 720
ALT, IU/L
Median 29 26 75 84 43 103 n.a. 74 23 n.a.
IQR 20, 43 18, 38 42, 139 56, 135 24, 88 69, 169 n.a. 48, 120 17, 31 n.a.
Total No. with data 3670 2794 2547 1495 1830 572 n.a. 1230 1259 n.a.
Albumin, g/L
Median 45 46 47 43 44 43 n.a. 39 44 n.a.
IQR 43, 47 43, 48 44, 49 41, 45 40, 46 40, 45 n.a. 35, 42 41, 46 n.a.
Total No. with data 3670 2793 2547 1495 1797 572 n.a. 1230 1259 n.a.
Total bilirubin,
lmol/L
Median 12.2 14.9 14.2 10.3 12.0 10.3 n.a. 13.0 10.3 n.a.
IQR 9.2, 16.6 11.3, 20.6 10.6, 19.5 8.6, 15.4 8.6, 17.1 6.8, 13.7 n.a. 9.0, 19.0 6.8, 17.1 n.a.
Total No. with data 3671 2790 2546 1495 1821 572 n.a. 1230 1259 n.a.
ALBI score
Median −3.1 −3.1 −3.2 −3.0 −3.0 −3.0 −3.0 −2.6 −3.1 −3.0
IQR −3.3, −2.9 −3.3, −2.9 −3.4, −3.0 −3.2, −2.8 −3.3, −2.7 −3.2, −2.8 −3.2, −2.8 −2.9, −2.2 −3.3, −2.8 −3.2, −2.7
Total No. with data 3669 2789 2546 1495 1763 572 1077 1230 1259 720
LSM, kPa
Median 7.2 7.2 n.a. n.a. n.a. n.a. n.a. n.a. 14.1 n.a.
IQR 5.5, 11.1 5.2, 12.0 n.a. n.a. n.a. n.a. n.a. n.a. 9.4, 21.3 n.a.
Total No. with data 3598 2451 n.a. n.a. n.a. n.a. n.a. n.a. 1063 n.a.
Follow-up, months
Median 42.7 50.7 105.4 55.3 91.2 63.4 67.1 38.9 33.6 60.0
IQR 35.5, 54.4 42.5, 55.0 100.8, 108.4 44.1, 60.8 61.0, 115.0 55.5, 94.2 19.6, 126.7 25.0, 51.1 27.6, 40.1 51.2, 61.5
HCC cases during
follow-up, n
95 54 67 27 139 8 94 57 71 19
For the characteristics of HBV-related parameters in the CHB cohorts, please see Table S1.
ALBI, albumin-bilirubin; ALT, alanine aminotransferase; CHB, chronic hepatitis B; HCC, hepatocellular carcinoma; LSM, Liver stiffness measurement; n.a., not applicable or not available; NVH, non-viral hepatitis; SVR, sustained
virologic response.
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Research Article Viral hepatitisbetween 1997 and 201618; and (ii) English participants of the
STOP-HCV cirrhosis study who had achieved an SVR. The STOP-
HCV cirrhosis study comprised patients with HCV cirrhosis
recruited from 31 liver clinics in the UK between January 2015
and July 2016. In both UK cohorts, the laboratory tests conducted
<1 year before treatment initiation were used for the analysis.
Follow-up time was commenced at the date of achieving an SVR.
Gilead HCV SVR cirrhotic cohort
This cohort enrolled patients with cirrhosis (93.7% Caucasians)
with or without decompensated liver disease who achieved an
SVR after receiving a sofosbuvir-based regimen without IFN
while participating in a Gilead-sponsored HCV study or
commercially at selected sites (NCT02292706). The laboratory
results collected at enrolment (i.e. after completing antiviral
treatment) were used for the analysis.
Patients with NVH
The origin of the cohort of patientswith NVHwas the same as that
of the Japanese HCV cohort. Most of these cases were attributable
to non-alcoholic fatty liver disease (NAFLD); excessive alcoholwas
considered an additional risk factor in 11% of cases.
Cirrhosis and HCC assessment
The diagnoses of cirrhosis and HCC were based on standard
histological and/or compatible radiological findings. Patients
underwent evaluation at least every 6 months. For detailed in-
formation, please see the supplementary material.
Albumin–bilirubin score calculation
The albumin–bilirubin (ALBI) score, a simple index reflecting the
underlying liver function, was calculated for each patient by the
following formula based on the albumin and bilirubin levels:
ALBI score¼ðlog10 bilirubin × 0:66Þ + ðalbumin × −0:085Þ;
where bilirubin is in lmol/L and albumin in g/L.19
Statistical analysis
Statistical analysis was performed using the Statistical Package
for the Social Sciences (SPSS version 20.0, Chicago, IL, USA) and R
(Version 3.5.1). Patients in each cohort who had a follow-up time
of less than 6 months or had been found to have HCC within 6
months were excluded from the analysis. Data were expressed asTable 2. Cox regression analysis in the training cohort.
Univariable analysis
Hazard ratio 95% CI p v
Cirrhosis (Yes vs. No) 6.826 4.492, 10.375 <0.
HBV DNA, per log10 IU/mL 0.917 0.812, 1.036
HBeAg (positive vs. negative) 0.382 0.226, 0.645 <0
HBsAg, per log10 IU/mL 0.771 0.635, 0.936 0
ALT, per IU/L 0.998 0.992, 1.003 0
LSM, per kPa 1.057 1.045, 1.068 <0.
Risk model parameters
Age, per year 1.083 1.064, 1.103 <0.
Sex (male vs. female) 2.513 1.222, 5.168 0
ALBI score 4.456 3.229, 6.149 <0.
Platelet, per 103/mm3 0.983 0.980, 0.987 <0.
ALBI, albumin-bilirubin; ALT, alanine aminotransferase; LSM, liver stiffness measureme
4 Journal of Hepatologycounts and percentages for categorical variables and as the
median and interquartile range (IQR) for continuous variables.
The cumulative probabilities of HCC occurrence at year 5 were
estimated by the Kaplan–Meier (K–M) method and compared
using the log-rank test.
Univariable and multivariable Cox proportional hazards
regression models were used to estimate the effects of various
variables on the hazard of HCC occurrence and to develop the
HCC prediction model. The patients from the centre with the
largest sample size (Nanfang Hospital, Guangzhou, China) in
the Search-B CHB cohort were used as the training cohort to
derive a score for predicting HCC within 5 years. The patients
from the other centres of the Search-B cohort and from the other
HBV, HCV and NVH cohorts/trials were used for the external
validation of the scoring system. The time-dependent receiver
operating characteristic (ROC) curve was used to evaluate the
prediction accuracy of the model. The performance of model
discrimination was assessed using Harrell's C-index. Z-score
tests were used to compare Harrell's C-index in different models.
A calibration plot was used to graphically assess the agreement
between the probability of remaining HCC free as predicted by
the model and the observed probability. X-tile plots were used
to generate 2 optimal cut-off values with the highest v2 value to
separate patients into low-, medium- and high-risk groups.20
The sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) were also estimated for the 2
optimal cut-offs of the risk model. For more information
regarding the development of the HCC risk score, please see the
supplementary material.
This study was approved by the Ethics Committee of Nanfang
Hospital, and was conducted in accordance with the guidelines
of the Declaration of Helsinki and the principles of good clinical
practice. All patients provided written informed consent to have
their data used (anonymously) for research purposes.
Results
In this study, a total of 17,374 patients, comprising 10,578 Asian
patients with CHB, 2,510 Caucasian patients with CHB, 3,566
patients with HCV and 720 patients with NVH, were included in
the analysis. Patients were grouped into 1 training cohort as well
as 3 Asian CHB, 2 Caucasian CHB, 3 HCV infection and 1 NVH
validation cohorts. Table 1 and Table S1 show the clinical and
laboratory data of each cohort. Other than the 2 HCV SVR
cirrhotic cohorts, the percentages of patients with cirrhosis in
the other cohorts ranged from 11.4% to 27.4%.Multivariable analysis
alue Coefficient Hazard ratio 95% CI p value
0001
0.168
.001
.009
.353
0001
0001 0.060 1.062 1.041, 1.084 <0.0001
.013 0.894 2.446 1.185, 5.046 0.016
0001 0.484 1.623 1.056, 2.493 0.028
0001 −0.012 0.988 0.985, 0.992 <0.0001
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In the training cohort, 95 patients developed HCC during a me-
dian follow-up time of 42.7 (IQR: 35.5, 54.4) months. The cu-
mulative 1-, 3- and 5-year incidences of HCC were 0.4%, 1.8% and
3.7%, respectively (Figure S1A). In the univariable Cox regression
analysis, age, sex, cirrhosis, HBeAg status, levels of quantitative
HBsAg, liver stiffness measurement (LSM), ALBI and platelets
were associated with HCC occurrence within year 5 (Table 2).
Patients with ALBI < −3 had significantly lower risk of HCC
compared with those with ALBI >− −3 (5-year cumulative in-
cidences of HCC: 2.0% vs. 6.5%, p <0.0001) (Figure S2).co
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Derivation of the HCC risk score
Considering that the cirrhosis diagnosis in clinical practice is
relatively subjective, and the LSM level is not easily accessible in
most primary care settings, we confined our risk score to the
following non-viral variables: age, sex, ALBI and platelets. ALBI
and platelets are variables that reflect the underlying liver
function and fibrosis stage, respectively.
A risk score, known as the age–male–ALBI–platelets (aMAP)
score, was devised using the above 4 variables weighted by their
regression coefficients in the multivariable Cox model (Table 2),
and then the score range was standardised to 1–100:
aMAP risk score¼ðf0:06 × age + 0:89 × sex ðMale: 1; Female: 0Þ
+0:48 × ½ðlog10 bilirubin × 0:66Þ
+ ðalbumin × −0:085Þ −0:01
×plateletsg + 7:4Þ =14:77 ×100;
where age is in year, bilirubin in lmol/l, albumin in g/l and
platelets in 103/mm3. The 5-year baseline survival function of the
aMAP Risk Score was:
S0ðtÞ¼ expð−H0ðtÞÞ ¼0:984:
The C-index of the aMAP score was 0.82 (95% CI: 0.77–0.86).
The C-index did not improve substantially when cirrhosis (0.82,
95% CI: 0.78–0.87) or the LSM value (0.82, 95% CI: 0.78–0.87) was
included in the model. The C-index was 0.80 (95% CI: 0.74–0.87)
and 0.84 (95% CI: 0.77–0.90) among patients with or without
achieving a negative HBV DNA status, respectively, and 0.74 (95%
CI: 0.67–0.81) and 0.75 (95% CI: 0.67–0.84) in patients with and
without cirrhosis, respectively (Table 3). The time-dependent
ROC curves of aMAP score for predicting 1-, 2-, 3-, 4- and 5-
year HCC showed that the prediction model had good predic-
tion accuracy during each period of follow-up (Figure S3).Ta
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HCC risk stratification based on the aMAP score
The X-tile plots were used to generate 2 optimal cut-off values
(50 and 60) to separate the training cohort into low-, medium-
and high-risk groups (Figure S4). Figure S5 also showed that the
HCC risk increased significantly when the aMAP score was either
50 or 60. Of the 3,662 patients with evaluable aMAP risk scores,
2,158 (58.9%), 1,181 (32.3%) and 323 (8.8%) were assigned to the
low-, medium- and high-risk groups, respectively. The 5-year
cumulative incidences of HCC were 0.8% (95% CI: 0.3–1.3%), 4.2%
[95% CI: 2.6–5.7%; hazard ratio (HR) = 5.1 (95% CI: 3.3–8.0)] and
19.9% [95% CI: 12.8–26.5%; HR = 27.1 (95% CI: 12.5–58.8)] in the
low-, medium- and high-risk groups, respectively (p <0.0001)Journal of Hepatology 2020 vol. - j 1–11 5
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Fig. 1. Cumulative risk of HCC according to the aMAP scores in each cohort. (A) Search-B training cohort, (B) Search-B validation cohort, (C) REALM cohort, (D)
Gilead Asian chronic hepatitis B virus (CHB) cohort, (E) European PAGE-B cohort, (F) Gilead Caucasian CHB cohort, (G) Japanese HCV cohort, (H) UK sustained
virological response (SVR) cirrhotic cohort, (I) Gilead SVR cirrhotic cohort and (J) non-viral hepatitis (NVH) cohort.
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(Figure 1A). The cut-off value of 50 was associated with a
sensitivity of 86.5% and an NPV of 99.5%. The cut-off value of 60
resulted in a specificity of 92.2% and a PPV of 13.3% (Table 4). The
calibration plot for the 5-year probability of remaining free of
HCC performed well in the training cohort (Figure 2A).
External validation of the aMAP risk score in the CHB, HCV
and NVH validation cohorts
The 3- or 5-year HCC incidences in the 9 validation cohorts
ranged from 1.3% to 7.0% (Figure S1B–J).
In the 3 Asian and 2 Caucasian CHB validation cohorts, the
aMAP score performed well in predicting HCC development, with
C-index values ranging from 0.82 to 0.87. Similarly, the C-index
values were 0.85 (95% CI: 0.79–0.91) and 0.85 (95% CI: 0.79–0.90)
in the Japanese HCV and NVH validation cohorts, respectively.
Within the subgroup of patients with cirrhosis, the C-index values
for predicting HCC ranged from 0.61 to 0.83 (Table 3).
Among the 13,324 patients with evaluable aMAP scores in the
validation cohorts, 5,255 (39.4%), 5,348 (40.1%) and 2,721 (20.4%)
of the overall validation population were assigned to the low-,
medium- and high-risk groups, respectively. The K–M curves also
showed equally good discrimination among the 3 risk groups in
the validation cohorts. The 3- or 5-year cumulative incidences of
HCC were 0–0.8%, 1.5–4.8% and 8.1–17.8% in the low-, medium-
and high-risk groups, respectively (all p <0.0001) (Figure 1B–J). In
the 9 validation cohorts, the cut-off value of 50 was associated
with a sensitivity of 85.7–100% and an NPV of 99.3–100%. The
cut-off value of 60 resulted in a specificity of 56.6–95.8% and a PPV
of 6.6–15.7% (Table 4). The calibration plots of the model in the
validation cohorts are depicted in Figure 2B–J.
Comparison of the predictive performance of the aMAP score
and other existing HBV-related HCC risk scores
The 6 existing HBV-related HCC risk scores [Risk Estimation for
HCC in Chronic Hepatitis B (REACH-B), Chinese University HCCTable 4. Accuracy for prediction of hepatocellular carcinoma development in
50 and 60.
aMAP score
Cut-off value: 50 Cut-off value: 60 Cut-off valu
Value 95% CI Value 95% CI Value 9
Search-B training cohort Search
Sensitivity, % 86.5 79.4, 93.6 48.3 37.9, 58.7 92.5 85.3
Specificity, % 60.4 58.8, 61.9 92.2 91.3, 93.1 42.4 40.6
PPV, % 5.1 4.0, 6.2 13.3 9.6, 17.0 3.0 2
NPV, % 99.5 99.1, 99.8 98.6 98.2, 99.0 99.7 99.3
Gilead Asian CHB cohort Euro
Sensitivity, % 87.5 74.3, 100 37.5 18.1, 56.9 95.5 91.1
Specificity, % 63.6 61.2, 66.1 95.8 94.8, 96.8 35.0 32.7
PPV, % 3.8 2.2, 5.4 12.7 4.9, 20.4 7.2 5.
NPV, % 99.7 99.3, 100 98.9 98.4, 99.5 99.3 98.7
Japanese HCV cohort UK
Sensitivity, % 97.1 91.4, 100 82.4 69.5, 95.2 98.2 89.4
Specificity, % 22.0 19.4, 24.5 67.9 65.0, 70.7 14.3 12.4
PPV, % 3.9 2.6, 5.2 7.7 5.0, 10.5 5.3 4
NPV, % 99.6 98.7, 100 99.2 98.5, 99.8 99.4 96.
Japanese NVH cohort
Sensitivity, % 100 100, 100 78.9 60.6, 97.3
Specificity, % 30.5 27.1, 33.9 69.8 66.4, 73.2
PPV, % 3.8 2.1, 5.4 6.6 3.4, 9.8
NPV, % 100 100, 100 99.2 98.4, 100
CHB, chronic hepatitis B; NPV, Negative predictive value; NVH, non-viral hepatitis; PPV
Journal of Hepatology(CU-HCC), Liver Stiffness Measurement HCC (LSM-HCC), modi-
fied REACH-B (mREACH-B), PAGE-B and modified PAGE-B
(mPAGE-B) scores] were each calculated on the basis of the
clinical and laboratory parameters collected (Table S2).
In the training cohort, the C-index of the aMAP score was
significantly higher than those of the other HCC risk scores [p
<0.0001 (vs. REACH-B), p <0.0001 (vs. CU-HCC); p = 0.016 (vs.
LSM-HCC); p = 0.027 (vs.mREACH-B); p = 0.041 (vs. PAGE-B); and
p = 0.049 (vs. mPAGE-B)] (Table 5). The time-dependent AUC
curve analyses showed that the aMAP score obtained the highest
AUCs in dynamic trends among all risk scores within 5 years
(Figure S6). Compared with the mPAGE-B score, which had the
second highest C-index value, the aMAP score could identify a
significantly higher percentage of patients with a low HCC risk
(58.9% vs. 53.3%, p <0.001) (Figure S7). Moreover, compared with
the other 6 existing risk scores, the aMAP score also showed
significantly, or a trend towards, better performance for pre-
dicting HCC in the both Asian and Caucasian HBV validation
cohorts and their subgroups (Table 5 and Table S3).Discussion
In this study, we developed and externally validated a simple,
objective and accurate prognostic tool (called the aMAP score)
comprising routinely available laboratory parameters (albumin,
bilirubin and platelets) plus age and sex that could satisfactorily
predict the risk of HCC development among over 17,000 patients
with viral hepatitis and NVH from 11 global prospective studies.
Our findings showed that the aMAP score had excellent
discrimination and calibration in assessing the 5-year HCC risk
among all the cohorts irrespective of aetiology and ethnicity. To
our knowledge, this is the first study to assess the performance
of an HCC risk score among patients with differing aetiologies
and ethnicities as well as the first-ever data on a HCC risk score
from mainland China.the training and validation cohorts using the aMAP score cut-off values of
e: 50 Cut-off value: 60 Cut-off value: 50 Cut-off value: 60
5% CI Value 95% CI Value 95% CI Value 95% CI
-B validation cohort REALM cohort
, 99.6 64.2 51.2, 77.1 91.4 82.2, 100 28.6 13.6, 43.5
, 44.2 85.3 84.0, 86.6 63.8 61.9, 65.7 95.3 94.5, 96.2
.1, 3.8 7.7 5.2, 10.1 3.4 2.2, 4.6 7.9 3.2, 12.6
, 100 99.2 98.9, 99.6 99.8 99.6, 100 99.0 98.6, 99.4
pean PAGE-B cohort Gilead Caucasian CHB cohort
, 99.8 72.7 63.4, 82.0 85.7 59.8, 100 42.9 6.2, 79.5
, 37.3 79.3 77.3, 81.2 67.0 63.1, 70.9 95.7 94.1, 97.4
7, 8.7 15.7 12.2, 19.2 3.1 0.7, 5.6 11.1 0, 23.0
, 100 98.2 97.5, 98.9 99.7 99.2, 100 99.3 98.5, 100
SVR cirrhotic cohort Gilead SVR cirrhotic cohort
, 99.9 78.9 65.8, 88.2 100 94.4, 100 64.6 52.5, 75.1
, 16.5 61.7 58.9, 64.5 9.5 7.9, 11.3 56.6 53.8, 59.4
.0, 6.8 9.1 6.8, 12.1 5.7 4.5, 7.2 7.5 5.6, 10.0
2, 100 98.4 97.1, 99.1 100 96.7, 100 96.7 95.1, 97.8
, positive predictive value; SVR, sustained virologic response.
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Fig. 2. Calibration curves of the aMAP score to predict HCC in each cohort. (A) Search-B training cohort, (B) Search-B validation cohort, (C) REALM cohort, (D)
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Research Article Viral hepatitisIn recent decades, the healthcare costs of chronic disease have
increased yearly. Promoting early screening and developing
individualised HCC surveillance strategies remain the most cost-
effective measures for reducing HCC-related mortality. A previ-
ous study showed that annual or semi-annual surveillance is
considered cost-effective when the annual incidence of HCC8 Journal of Hepatologyexceeds 1–2%.21,22 By using the aMAP score, we identified a
group of low-risk patients (aMAP score <50) who accounted for
~45% of the overall population with an HCC probability of <0.2%
per year, meaning that approximately half of patients with
chronic hepatitis could undergo less intensive HCC surveillance.
By contrast, patients who are classified in the high-risk group2020 vol. - j 1–11
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Journal of Hepatology(aMAP score >60) should undergo intensive surveillance to
detect early HCC. We believe that a surveillance strategy based
on the aMAP risk score could direct limited resources to the right
population, thereby significantly reducing the healthcare burden
in each country.
Cirrhosis and LSM values are well-known risk factors for HCC,
as confirmed in our study. However, the diagnosis of cirrhosis in
clinical practice is subject to substantial inter- and intra-observer
variations, especially for cirrhosis at an early stage, and the LSM
value is not easily accessible in most primary care settings. Ac-
cording toour results, the additionof the cirrhosis or LSMvaluedid
not substantially improve the predictive power of the aMAP score.
Furthermore, some variables, such as viral status and alanine
aminotransferase levels, can change dramatically with the initia-
tion orwithdrawal of treatment. Therefore, although the cirrhosis,
LSM values and virus-related variables were related to future HCC
development, our study suggests that the aMAP score, which in-
cludes only objective clinical and laboratory parameters that are
not usually affected by antiviral treatment, is more suitable for
patients in the antiviral treatment era when the impact of aetio-
logical factors is diminishing. Indeed, the aMAP score demon-
strated significantly better and more stable predictive
performance for HCC development compard with the other HBV-
related HCC risk prediction models not only in the CHB training
cohort, but also in each of theCHB independent validation cohorts,
irrespective of ethnicity. The aMAP score also identified signifi-
cantly more patients at low HCC risk, suggesting that more pa-
tients should be exempted from intensive HCC surveillance. Given
that the aMAP score performed well irrespective of HBV DNA
status, it could be applied at different stages of treatment. More
importantly, this viral factor-free score also showed an excellent
performance in predicting HCC risk in patients with either HCV or
NVH. The different characteristics, treatment strategies and
recruitment periods of each independent cohort further
strengthen the reliability of our score. All the above evidence
supports the finding that the aMAP score is a reliable tool that can
accurately stratify HCC risk caused by HBV, HCV or NAFLD, which
are the leading risk factors for HCC worldwide.
The aMAP score involves just 2 laboratory parameters, the
ALBI score and platelets. The ALBI score was originally developed
to predict prognosis in patients with HCC in an international
setting.19 It is a simple, evidence-based and objective index and
can reflect the underlying liver function of patients at all disease
stages. A growing body of studies has demonstrated that ALBI
grade is also predictive of survival in patients with advanced
liver disease without HCC.23,24 In the current study, we demon-
strated that ALBI score was associated with HCC development
and included it in the aMAP risk score. Platelets are a well-
known parameter associated with the fibrosis stage. These ob-
servations suggest that the aMAP score is an objective index
reflecting both liver function and fibrosis stage. Furthermore, the
components of the model imply that liver function is worthy of
investigation as another, perhaps major, determinant of HCC risk.
However, the total bilirubin level could be influenced by certain
diseases, such as haemolysis and inherited enzyme defects.
Therefore, it is recommended that the aMAP score is not suitable
for predicting HCC risk among patients with non-liver diseases
that could significantly affect the bilirubin level.
Despite the significant findings in this report, our study also
has a few limitations. First, the patients were recruited from
tertiary hospitals and were especially likely to have active2020 vol. - j 1–11 9
Research Article Viral hepatitisdisease before treatment. It is likely that more patients would
belong to the low-risk category in a primary care setting, which
would further increase the NPV of the score. Second, similar to
existing HCC risk scores, the PPV value of the aMAP score at a
cut-off value of 60 was not optimal. We plan to combine other
variables (such as LSM, circulating cell-free DNA signatures,
proteins or metabolites) with the aMAP score to further improve
the PPV among patients in the high-risk group. Third, the
discriminatory ability of the aMAP score was suboptimal in the
case of patients with cirrhosis, a situation common to existing
HCC risk scores. One of the possible reasons is that the cirrhosis
diagnosis might be inaccurate, especially in routine clinical
practice. Fourth, most patients in this study were Asians and
Caucasians with viral hepatitis. Therefore, the performance of
the aMAP score in patients of other ethnicities (e.g. African) and
other aetiologies (e.g. NAFLD, primary biliary cirrhosis, etc.) re-
quires further investigation. Fifth, the laboratory data were
collected at different time points across different cohorts, which
might weaken the reliability of the study results. Finally, the
formula for the aMAP score is relatively complex. However, the
parameters included in the score are very common, and a mobile
app or web-based calculator could calculate the score easily and
rapidly in the current high-tech era. In the future, we could also
merge the aMAP score into liver function test panels or hospital
electronic systems to facilitate its implementation and guide
patient management in clinical practice.
In conclusion, the aMAP score is the first risk score to facili-
tate accurate, reliable and simple-to-use prediction of the risk of
HCC development irrespective of aetiology and ethnicity. It is
entirely objective, being based on 5 routine clinical and labora-
tory parameters without the inclusion of viral factors. Thus, this
score will be a useful tool for realising individualised HCC sur-
veillance to improve early HCC detection and reduce mortality,
ultimately helping to achieve the ambitious goals of the WHO to
reduce hepatitis-related mortality by 65% by 2030.
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